[AGEN] Agenus Inc.


Type of security: Stock

Sector: Health Care

Industry: Biotechnology: Biological Products (No Diagnostic Substances)

Market Capitalization: 408.34 M

Exchange: NASDAQ

The data is delayed by 15 minutes.


Price: 4.4 Change: 0.34 (8.37%)
Ext. hours: Change: 0 (0%)

chart AGEN

Refresh chart

Strongest Trends Summary For AGEN

AGEN is in the long-term down -64% below S&P in 7 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: Agenus Inc., a biopharmaceutical company, is developing a portfolio of immuno-oncology candidates, including checkpoint modulators (CPMs), heat shock protein vaccines, and adjuvants. Its proprietary discovery engine Retrocyte Display is designed to generate therapeutic antibody drug candidates incorporating full-length IgG format human antibody libraries expressed in mammalian B-lineage cells. The company?s portfolio of checkpoint modulator programs is advancing in preclinical development. Its heat shock protein vaccines for cancer and infectious disease are in Phase II studies. The company?s QS-21 Stimulon adjuvant platform, which is partnered with GlaxoSmithKline and Janssen, includes various candidates in Phase III trials. In addition, it has 23 programs are in clinical development. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding86.88 M EPS-1.28 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 28.59% Sales Growth - Q/Q144.16% P/E-2.7
P/E To EPS Growth P/S40 P/BV8.83 Price/Cash Per Share
Price/Free Cash Flow-9.95 ROA-51.88% ROE-131.58% ROI
Current Ratio4.06 Quick Ratio4.05 Long Term Debt/Equity Debt Ratio0.45
Gross Margin Operating Margin-507.29% Net Profit Margin-596.23% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities36.1 M Cash From Investing Activities14.21 M Cash From Operating Activities3.3 M Gross Profit
Net Profit-40.41 M Operating Profit-33.2 M Total Assets117.32 M Total Current Assets85.15 M
Total Current Liabilities21 M Total Debt11.5 M Total Liabilities71.07 M Total Revenue6.38 M
Technical Data
High 52 week6.04 Low 52 week1.59 Last close2.66 Last change0%
RSI32.39 Average true range0.12 Beta1.14 Volume925.23 K
Simple moving average 20 days-2.22% Simple moving average 50 days-6.96% Simple moving average 200 days-17.66%
Performance Data
Performance Week4.72% Performance Month-6.99% Performance Quart-21.53% Performance Half60.24%
Performance Year-35.12% Performance Year-to-date11.76% Volatility daily2.12% Volatility weekly4.75%
Volatility monthly9.73% Volatility yearly33.72% Relative Volume223.31% Average Volume1.27 M
New High New Low


2020-06-03 07:39:19 | The Daily Biotech Pulse: Regulatory Delay For Novartis' Multiple Sclerosis Drug, FSD Gets Nod For COVID-19 Study

2020-06-02 11:30:03 | Has Agenus AGEN Outpaced Other Medical Stocks This Year?

2020-06-02 08:30:00 | FDA Clears IND for iNKT Cells to Treat COVID-19 Patients

2020-06-01 09:21:01 | Is the Options Market Predicting a Spike in Agenus AGEN Stock?

2020-05-29 13:28:00 | Here's Why Agenus Rose as Much as 23.3% Today

2020-05-29 09:43:01 | Protalix Submits BLA for Fabry Disease Candidate PRX-102

2020-05-29 08:00:00 | ASCO Presentation of Agenus' AGEN1181 by Dr. Steven O'Day

2020-05-28 09:42:01 | Mersana Stock Spikes on Interim Data on Cancer Candidate

2020-05-28 09:10:01 | Ironwood to Halt MD-7246 Development After Study Failure

2020-05-14 11:56:03 | Agenus' AGEN IND for iNKT Therapy Gets FDA Acceptance

2020-05-14 08:00:00 | Agenus NextGen CTLA-4 Antibody AGEN1181 Data to be Presented at ASCO

2020-05-13 09:54:00 | FDA Clears AgenTus IND for Allogeneic iNKT Cell Therapy

2020-05-13 09:43:01 | Agenus AGEN: Strong Industry, Solid Earnings Estimate Revisions

2020-05-11 12:00:04 | Agenus AGEN Upgraded to Buy: Here's Why

2020-05-08 19:30:38 | Agenus Inc AGEN Q1 2020 Earnings Call Transcript

2020-05-08 01:11:05 | Edited Transcript of AGEN earnings conference call or presentation 7-May-20 12:30pm GMT

2020-05-07 09:35:01 | Agenus AGEN Reports Q1 Loss, Tops Revenue Estimates

2020-05-07 08:29:11 | Recap: Agenus Q1 Earnings

2020-05-07 08:00:00 | Agenus First Quarter Results and Update

2020-04-30 12:34:04 | Analysts Estimate Agenus AGEN to Report a Decline in Earnings: What to Look Out for

2020-04-28 11:50:00 | Agenus to Report First Quarter 2020 Financial Results on May 7, 2020 and Host Conference Call and Webcast

2020-04-16 08:56:12 | Agenus' Shares March Higher, Can It Continue?

2020-04-16 08:38:12 | Are Options Traders Betting on a Big Move in Agenus AGEN Stock?

2020-04-07 13:04:00 | Agenus Receives Fast Track Designation for Balstilimab in Advanced Cervical Cancer

2020-04-06 09:00:01 | Why Agenus AGEN Stock Might be a Great Pick

2020-03-24 12:00:04 | Agenus AGEN Moves to Buy: Rationale Behind the Upgrade

2020-03-19 16:05:39 | Edited Transcript of AGEN earnings conference call or presentation 12-Mar-20 12:30pm GMT

2020-03-16 06:09:37 | Agenus Inc. Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

2020-03-13 11:57:03 | Agenus AGEN Q4 Earnings Beat Estimates, Revenues Rise Y/Y

2020-03-12 10:05:02 | Agenus AGEN Reports Q4 Loss, Tops Revenue Estimates

2020-03-12 07:45:00 | Agenus Receives Fast Track Designation for Balstilimab & Zalifrelimab in Advanced Cervical Cancer

2020-03-12 07:30:00 | Agenus Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update

2020-03-10 09:14:00 | First QS-21 Royalty Payment Due to Agenus is Triggered

2020-03-05 12:30:05 | Earnings Preview: Agenus AGEN Q4 Earnings Expected to Decline

2020-03-03 08:00:00 | Agenus to Report Fourth Quarter and Full Year 2019 Financial Results on March 12, 2020 with Conference Call and Webcast

2020-02-28 08:58:01 | Immunomedics IMMU Reports Wider-Than-Expected Q4 Loss

2020-02-27 09:10:02 | Global Blood GBT Q4 Earnings Miss, Voxelotor Gets FDA Nod

2020-02-27 09:07:02 | Horizon Therapeutics' HZNP Q4 Earnings Beat Estimates

2020-02-21 12:00:05 | Agenus AGEN Upgraded to Strong Buy: What Does It Mean for the Stock?

2020-02-20 09:56:00 | Agenus Announces Positive Interim Data from Balstilimab and Zalifrelimab Clinical Trials in Second-Line Cervical Cancer

2020-02-06 15:12:00 | Agenus Announces Investor Day on February 20, 2020

2020-01-17 05:12:25 | Did You Manage To Avoid Agenus's NASDAQ:AGEN 22% Share Price Drop?

2020-01-09 10:59:00 | Agenus Announces the Appointment of Dr. Jennifer Buell to the position of President and COO

2020-01-09 09:48:02 | Agenus Initiates Phase I Study on Oncology Candidate AGEN1223

2020-01-08 10:04:03 | Amicus FOLD Provides Updates on AT-GAA for Pompe Disease

2020-01-08 08:30:00 | Agenus Commences Phase 1 trial with AGEN1223

2020-01-03 10:54:03 | Innate Pharma's Filing for Leukemia Drug Accepted in Europe

2020-01-03 09:55:02 | Pulmatrix Surges on License Agreement With Johnson & Johnson

2020-01-03 09:41:02 | Amicus Progresses on Pipeline Development Amid Competition

2020-01-03 09:01:02 | Arena ARNA Expands Strategic Deal With Beacon Discovery